Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks Kiwi
I am familiar with this latest discovery but always nice to hear it again
Bought 20,000 lottery ticket in this one.
Not really
My antibody test is negative indicating no exposure.
Yes.
I think my kids had it as well but i have been negative so far. Weird
You need CVOT trial. Why do you need another epa when everyone will use generic vascepa? What is the advantage?
Yes. Every week
Also reps are back in field.
Obviously you don’t understand how medicine works
I prescribe medications every day. How about you?
You need an outcome study otherwise nobody will prescribe it.
And no outcome study. Useless.
Please fedex one to judge Du as well. Just in case. Make a copy of nature article.
Not familiar
I like myocardia myok
Thanks
Wife is great. Will let her our of isolation on Wednesday.
Yes glad i nailed TRVN.
Lol. You forgot UV light
What part of “it doesn’t work” you don’t understand? We used it for 3 months. Garbage.
Excellent. Enjoy your gains.
No worries bro. I am from nyc but live in Florida now. Enjoy your gains.
Yeah wife recovered completely. Hope you made some dough on TRVN.
Are you in NYC?
I did very well on friday
Made up all of my AMRN loses.
BO at $20 would be great. Not selling a single share.
Yes the problem was late FDA approval on December 15 after Amarin already signed all contracts for 2020. 2021 will be much easier.
Agree. However the lack of insurance coverage is even bigger part of the lower than expected sales. I have numerous rejections and I don’t even write Vascepa for any patients with Humana. There is no point. Most insurances are still paying under the Marine label. Hopefully, they can negotiate better deals for 2021
I am one anecdotal evidence
Europe does not rely much on promotions.
Healthcare is provided by the government.
Healthcare in Europe is not for profit unlike US.
They will push vascepa because it will save them money.
GIA the best option for Europe due to differences in healthcare systems between US and Europe.
GIA. Excellent news. Healthcare system in Europe is not for profit. Meds covered by the government. Smart move.
Thanks
Taking care of me was the point of me going somewhere, be it only 50 minutes away from home.
No time off Since September 2019.
I think you should be good
Use Rz mask when you go to stores.
Did you get any masks?
We are both O positive
Thanks a lot
The room was clean when we got in and then my wife wiped most of surfaces with lysol wipes
TV remote was wrapped in a clean nylon bag.
We had option of not using room cleaning services.
It was Hilton. I felt they were on top of things.
You sent me an opinion, not study.
Everyone has an opinion on HCQ, even Trump
What counts is a positive RCT study.
How about matinas do observational retrospective study which is positive.
They include Reduce IT population. Positive study. Apply to FDA and ask for REDUCE It indication.
What would you say?
What would amarin say?
What would the FDA say?
All of 3 would say GTFOH
Thank you
Plus it is natural product and not harmful medication. If it does not work, no big deal.
If it works, good.
On the other hand, HCQ prolonges QT interval that leads to Torsade du Pointes arrhythmia and you die in few seconds.
HCQ PLUS Z Pack is a recipe for disaster and quick death.
Hydroxychloroquine/chloroquine — We suggest not using hydroxychloroquine or chloroquine in hospitalized patients given the lack of clear benefit and potential for toxicity. In June 2020, the US FDA revoked its emergency use authorization for these agents in patients with severe COVID-19, noting that the known and potential benefits no longer outweighed the known and potential risks [54].
Both chloroquine and hydroxychloroquine may inhibit SARS-CoV-2 in vitro [55]. However, accumulating data from controlled trials suggest that they do not provide a clinical benefit for patients with COVID-19 [56-60]. According to a preliminary, unpublished report from a large randomized trial evaluating a number of potential therapies for hospitalized patients with COVID-19, there was no difference in 28-day mortality among 1561 patients who were randomly assigned to receive hydroxychloroquine compared with 3155 patients who received standard care (26.8 versus 25 percent, rate ratio 1.09, 95% CI 0.96-1.23); hydroxychloroquine also did not decrease length of hospital stay [56]. Based on these data, the hydroxychloroquine arm of the trial was closed. The World Health Organization also terminated the hydroxychloroquine arm of its large SOLIDARITY trial, and the United States National Institutes of Health terminated its trial of hydroxychloroquine in hospitalized patients; each cited a lack of benefit based on preliminary data from the trials [57,58,61]. In another open-label trial of hospitalized patients who required no or only low-flow oxygen supplementation (≤4 L/min), hydroxychloroquine (with or without azithromycin) did not improve clinical status at 15-day follow-up compared with standard of care [60].
Observational data are somewhat mixed and have methodologic limitations, but also suggest no benefit with hydroxychloroquine or chloroquine [62-67]. As an example, in an observational study of nearly 1400 patients with COVID-19 admitted to a hospital in New York, hydroxychloroquine use was reported in 811 patients and was associated with a higher risk of intubation or death (HR 2.37) [64]. Patients who received hydroxychloroquine were older, were more likely to have comorbidities, and had more severe illness than those who did not, which were likely confounding variables; in a multivariate analysis comparing those patients with a propensity score-matched subset of 274 patients who did not receive hydroxychloroquine, there was no association between hydroxychloroquine use and intubation or death (adjusted HR 1.04).
In contrast, in one retrospective study of over 2500 patients hospitalized with COVID-19 in Michigan, protocol-driven hydroxychloroquine administration for severe disease with close telemetry monitoring was associated with decreased mortality (propensity-score adjusted HR 0.34) [67]. However, potential confounders (including substantially more glucocorticoid administration among those who received hydroxychloroquine and uncertain reasons why some patients with severe disease did not receive hydroxychloroquine per protocol) limit confidence in these findings, particularly in light of randomized trial results.
Studies have highlighted the toxicity of hydroxychloroquine or chloroquine [66,68]. One trial comparing two doses of chloroquine for COVID-19 was stopped early because of a higher mortality rate in the high-dose group [68]. QTc prolongation, arrhythmias, and other adverse effects associated with hydroxychloroquine and chloroquine are discussed in detail elsewhere. (See "Coronavirus disease 2019 (COVID-19): Arrhythmias and conduction system disease", section on 'Patients receiving QT-prolonging treatments' and "Antimalarial drugs in the treatment of rheumatic disease", section on 'Adverse effects' and "Methemoglobinemia", section on 'Dapsone and some antimalarials'.)
The evidence on the combination of hydroxychloroquine and azithromycin is discussed elsewhere. (See 'Others' below.)
That does not count either.
Sorry we have gold standards here:
Randomized
Controlled
Double blind study
Everything else is pure speculation.
Run one, achieve statistically significant results and you will prove your point.
You guys invest in Amarin based on REDUCE IT study data. Have some common sense.
The strength trial failed. Show we substitute VASCEPA FOR EPINOVA?
According to you that would be fine.
Show me those studies that prove your point? Anything to back up your claims? Angry wodoo Nigerian doc does not count
P value 0.35
You need p value 0.05.
Failed.
Next?
It is safe drug but but it does not work. So no indication to give for COVID based on 5 failed randomized controlled studies.
HCQ safe, does not work.
We drove. Marco Island is 50 minute drive.
I calculated and feel she picked it up on July 11 in that restaurant. The only time we ate inside. That was a big mistake. Always eat outside.
Jomama
Most table waiting staff wears masks with their noses totally exposed.
We arrived July 11
Left July 21
Symptoms appeared July 25th.
It looks like it may have been that inside dinning option we had on July 11, with waiters wearing their masks inappropriately. Plus those are only cloth self-made masks which, IMO, offer no protection.
Whal
Am I safer seeing on average 8 covid positive patients a day, seeing 20 patients in my office or 100 per week (full exam including the heart where our heads are close, unknown covid status, seeing another 30 inpatients with unknown covid status per day. We are talking about 300 patient contacts a week.
Or am I safer going to a hotel where we did not allow cleaning services to come in at all, always had masks on except that one time when we sat inside. Going to a beach with next people being at least 15 feet away. Never taking to anyone without a mask on.
Cardiac surgeons usually don't prescribe chronic cardiac medictions. Cardiologist s do. So it is ok if he is not interested.